Luvometinib, Cytarabine.
Phase 2
Luvometinib, Cytarabine. is one of 21 therapeutic programs targeting Langerhans Cell Histiocytosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
20 competitors in Langerhans Cell Histiocytosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Tabloid
Akero TherapeuticsApproved
Decadron
AAspen Global Incorporated
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Trexall
Jazz PharmaceuticalsPhase 3
Cytosar
TevaPhase 3
Velban
Eli LillyPhase 3
Rayos
RRoxane Laboratories
Phase 3
Purinethol
SStason
Phase 3
Indocin
CCosette Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Luvometinib, Cytarabine.. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]